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Background: Production of monoterpenoids as valuable chemicals using recombinant microbes is a growing field
of interest. Unfortunately, antimicrobial activity of most monoterpenoids hampers a wide application of
microorganisms for their production. Strains of Pseudomonas putida, a fast growing and metabolically versatile
bacterium, often show an outstanding high tolerance towards organic solvents and other toxic compounds.
Therefore, Pseudomonas putida constitutes an attractive alternative host in comparison to conventionally used
microorganisms. Here, metabolic engineering of solvent tolerant Pseudomonas putida as a novel microbial cell
factory for de novo production of monoterpenoids is reported for the first time, exemplified by geranic acid
production from glycerol as carbon source. The monoterpenoic acid is an attractive compound for application
in the flavor, fragrance, cosmetics and agro industries.
Results: A comparison between Escherichia coli, Saccharomyces cerevisiae and Pseudomonas putida concerning
the ability to grow in the presence of geranic acid revealed that the pseudomonad bears a superior resilience
compared to the conventionally used microbes. Moreover, Pseudomonas putida DSM 12264 wildtype strain efficiently
oxidized externally added geraniol to geranic acid with no further degradation. Omitting external dosage of geraniol
but functionally expressing geraniol synthase (GES) from Ocimum basilicum, a first proof-of-concept for de novo
biosynthesis of 1.35 mg/L geranic acid in P. putida DSM 12264 was achieved. Doubling the amount of glycerol
resulted in twice the amount of product. Co-expression of the six genes of the mevalonate pathway from Myxococcus
xanthus to establish flux from acetyl-CoA to the universal terpenoid precursor isopentenylpyrophosphate yielded
36 mg/L geranic acid in shake flask experiments. In the bioreactor, the recombinant strain produced 193 mg/L of
geranic acid under fed-batch conditions within 48 h.
Conclusion: Metabolic engineering turned Pseudomonas putida DSM 12264, a versatile monoterpenoid oxidation
biocatalyst, into an efficient microbial cell factory for de novo geranic acid production. Improvements by metabolic
and process engineering are expected to further increase the product concentration. To the best of the authors’
knowledge, this is the first example of a de novo production of a monoterpenoid with Pseudomonas putida and of
a microbial monoterpenoic acid synthesis in general.
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Terpenoids constitute the most diverse group of natural
products with more than 40,000 structurally different
molecules identified in nature [1], of which more than
1,000 compounds belong to the subclass of monoterpe-
noids [2]. Terpenoids are widely applied as flavor and
fragrance compounds, colorants, nutraceuticals, pharma-
ceuticals, agrichemicals etc. [1]. Since these biomolecules,
especially their oxyfunctionalized derivatives, are often
naturally produced in only small amounts, approaches for
their production others than isolation from natural raw
materials are very much sought. Since chemical synthesis
often starts from fossil raw materials and can be costly,
especially for stereo- and/or regioselectively oxyfunctio-
nalized terpenoids, biotechnological production starting
from cheap renewable substrates offers a highly attract-
ive alternative. In their pioneering work, J.D. Keasling
and co-workers comprehensively engineered Escherichia
coli and Saccharomyces cerevisiae towards microbial cell
factories for the production of the sesquiterpenoids
amorpha-4,11-diene and artemisinic acid [3-6]. Now-
adays, high concentrations regarding the production of
secondary metabolites of up to the grams per liter range
are reported for sesquiterpenoids already in shake flask
cultures [7-9], but monoterpenoid production using
similarly engineered microbial hosts as platform strains is
usually still limited to product titers in the lower milli-
grams per liter range [10,11]. The toxicity of monoterpe-
noids is referred to as the main bottleneck hampering
their efficient microbial production or biotransformation
[12,13]. It was shown that monoterpenoids, such as
thymol, menthol, linalyl acetate, α-pinene and β-pinene,
preferentially intercalate into the cell membrane resulting
in an increase of membrane fluidity which eventually leads
to loss of vital membrane functions and cell death [14-16].
For baker’s yeast, the cell wall instead of the membrane
was recently shown to be the site of the destructive action
of externally added limonene [17]. Pseudomonas putida,
a Gram-negative γ-proteobacterium, possesses the out-
standing ability to tolerate high concentrations of different
hydrocarbons, though great differences in the degree
of resilience occur among different strains. Several
mechanisms to counteract organic solvent toxicity are
described for P. putida such as reinforcing the membrane
phospholipid bilayer by cis-to-trans isomerization of un-
saturated fatty acids, increasing the ratio of saturated-
to-unsaturated fatty acids, and active export of toxic
compounds via efflux pumps [18,19]. A couple of industrial
processes with P. putida have already been established [20]
and more wildtype and recombinant P. putida strains have
been recently described for potential industrial de novo
production of toxic aromatic compounds such as phenol
[21] and p-hydroxybenzoate [22] or for biotransformation
of toxic precursors such as toluene to o-cresol [23] or themonoterpenoid limonene to perillic acid [24]. This
illustrates the potential of this species as an alternative
host for biotechnological applications, especially if
toxic substrates or products are dealt with. However,
de novo monoterpenoid production with P. putida has
not been reported until the present work.
The aim of our present study was to investigate the
potential of a solvent tolerant P. putida strain to be engi-
neered as a microbial cell factory for de novo production
of monoterpenoids. We chose P. putida DSM 12264 and
geranic acid as our model strain and product, respectively,
for three reasons: i) we knew from our previous work that
this strain is highly robust in the presence of limonene
even up to volume shares which form a distinct separate
organic phase in the bioreactor [24], ii) previous work
with this strain [25] as well as unpublished own pre-
investigations revealed that the wildtype strain is also
resilient against other monoterpenoids and it can convert
the monoterpene alcohol geraniol to geranic acid, and iii)
geranic acid has great potential for different industrially
relevant applications. Geranic acid can be used as a per-
fuming agent [26] and is an important building block for
the production of natural flavor esters [27]. Moreover, it
shows strong antifungal properties against two main
phytopathogens of corn, Colletotrichum graminicola
and Fusarium graminearum, and was therefore produced
in a transgenic maize plant to improve resistance against
the fungal attack [28]. Furthermore, this monoterpenoid is
known to inhibit tyrosinase, a key enzyme of melanogene-
sis in mammalian cells [29]. Lately, Choi showed that
geranic acid has depigmenting properties in melanocytes
combined with low cell toxicity which makes this com-
pound attractive as skin depigmentation agent [30].
Here, we introduced genes for a truncated geraniol
synthase (GES) from sweet basil Ocimum basilicum [31]
and the complete mevalonate (MVA) pathway from the
Gram-negative bacterium Myxococcus xanthus into P.
putida DSM 12264. The recombinant strain was able
to produce geranic acid without significant terpenoid
by-product formation and, due to its monoterpenoid
robustness, may serve as a platform strain for mono-
terpenoid production in the future.
Results
Suitability of P. putida as a host for geranic acid
production
To verify the expected advantage of P. putida for mono-
terpenoid production compared with conventional host
strains, i.e. an assumed superior product tolerance, growth
assays with P. putida DSM 12264, E. coli DH5α and S.
cerevisiae CEN.PK2-1C in the presence of geranic acid
were performed (Figure 1). According to Brennan and
colleagues, shake flasks with screw caps were used for
growth experiments to avoid monoterpenoid evaporation
Figure 1 Growth inhibition of S. cerevisiae, E. coli and P. putida
by geranic acid. Indicated are the ratios of the maximum growth
rate at given geranic acid concentrations (μmax) to the maximum
growth rate without monoterpenoid (μmax0) at different geranic acid
concentrations for S. cerevisiae, E. coli and P. putida. Cells were grown in
screw cap shake flasks in complex medium and different geranic acid
amounts were added at the beginning of the exponential phase.
Samples were taken for OD measurements to calculate μmax. Mean
values of two independent experiments, indicated by error bars,
are given.
Figure 2 Whole cell biotransformation of geraniol by P. putida
DSM 12264 wildtype strain. Indicated are the concentrations of
produced geranic acid at different time points by whole cell
biotransformation of geraniol by P. putida DSM 12264 wildtype.
Different amounts of geraniol were added to growing cells in E2
medium (containing 10% LB and 30 mg/L kanamycin, 4.6 g/L
glycerol) and geranic acid concentration was quantified after 8, 16,
32, 38 and 64 h. For 2, 4 and 8 mM geraniol, respectively, the last
sample was taken after 32 h due to complete geraniol depletion
and maximum product concentration. Experiments were run in
triplicates. For detailed statistical analysis, please see Additional file 1.
Mi et al. Microbial Cell Factories 2014, 13:170 Page 3 of 11
http://www.microbialcellfactories.com/content/13/1/170[32]. Growth of S. cerevisiae strongly decreased when
geranic acid concentrations were increased and was
completely inhibited at 2 mM geranic acid, whereas E.
coli growth became significantly affected by geranic acid
starting from concentrations of 5 mM and was com-
pletely inhibited at a concentration of 7 mM. For P.
putida, cell growth was distinctly impaired at 20 mM
but did not cease even at the highest geranic acid con-
centration tested, which was 40 mM.
To exclude biodegradation and bioconversion of the
desired product by P. putida DSM 12264, utilization of
geranic acid by this bacterium and product stability were
examined. Neither biodegradation nor bioconversion of
geranic acid was observed (data not shown). Furthermore,
P. putida KT2440 was also tested for geraniol oxidation,
since this strain is far better described in literature than
P. putida DSM 12264 [33]. This strain showed a geranic
acid tolerance similar to P. putida DSM 12264 and no
further metabolization of this monoterpenoic acid could
be observed as well (data not shown).
Biotransformation of geraniol to geranic acid by wildtype
P. putida DSM 12264
Pseudomonads are known to have strong oxidation
capabilities towards different hydrocarbons. Besides the
oxidation of monoterpene hydrocarbons, such as limon-
ene or the pinenes, Pseudomonas species have also been
shown to oxidize monoterpene aldehydes, such as citral or
citronellal, and monoterpene alcohols, such as linalool or
nerol [34]. To demonstrate the natural capacity of geraniol
oxidation in cells of P. putida DSM 12264, differentamounts of geraniol were added to growing cells in E2
medium and resulting geranic acid concentrations were
determined at different time points within 64 h (Figure 2).
Up to 16 mM geraniol were nearly completely oxidized
within the tested time period. With an initial substrate
concentration of 32 mM, a maximum product concentra-
tion of 23 mM was obtained. Furthermore, the oxidation
rate decreased at 32 mM and 64 mM (for t =8 h, geranic
acid concentrations were significantly (p <0.05, Tukey’s
HSD) lower than at 4 mM, 8 mM and 16 mM geraniol).
For more information about the statistical analysis, please
see Additional file 1. Cell growth slowed down at 8 mM
geraniol and was distinctly impaired at 16 mM (data not
shown). Cell lysis was observed at 32 mM and higher con-
centrations after 36 h (data not shown), while oxidation
rate decreased correspondingly.
These data illustrate the high geraniol oxidation capacity
of P. putida DSM 12264 with a maximum geranic acid
production rate over the first 32 h of ~0.43 mM/h. In con-
trast, an about 50% lower product formation rate and a
maximum product concentration of 5 mM geranic acid
were observed for P. putida KT2440 (data not shown).
Geranic acid production of P. putida DSM 12264
expressing GES
To implement de novo geraniol production in P. putida,
the gene of geraniol synthase (GES) from O. basilicum,
encoding the enzyme converting the cellular terpenoid
biosynthesis intermediate geranyl pyrophosphate (GPP) to
geraniol, was introduced via plasmid pMiS1 (Additional file 2).
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taining 10% LB) for 3 h, before gene expression was
induced by addition of 0.2% (w/v) L-rhamnose (t = 0,
Figure 3). A maximum concentration of 0.6 μM geraniol
was measured after 5 h followed by continuous deple-
tion, while geranic acid accumulated simultaneously,
ending up with a maximum concentration of 8 μM (ca.
1.3 mg/L) after about 21 h. No geraniol and geranic acid
was detected in cultures of P. putida DSM 12264 contain-
ing an empty vector (for statistical analysis, see Additional
file 3).
Geranic acid production in P. putida DSM 12264
coexpressing GES and MVA pathway
The efficiency of microbial terpenoid production is lim-
ited by the flux from intermediates of the central metab-
olism, i.e. acetyl-CoA (MVA pathway) or pyruvate and
glyceraldehyde-3-phosphate (2-C-methylerythritol-4-phos-
phate (MEP) pathway) towards the terpene synthase
substrates geranyl pyrophosphate (GPP), farnesyl pyro-
phosphate (FPP) or geranylgeranyl pyrophosphate (GGPP).
This has already been overcome by different approaches,
e.g. by overexpression of genes of the terpenoid biosyn-
thesis or the elimination of feedback inhibition mecha-
nisms [35]. The prime example of synthetic biology for
microbial terpenoid production is the successful heterol-
ogous expression of the MVA pathway in E. coli increasing
intracellular FPP concentration which greatly improved
the yield of sesquiterpene amorpha-4,11-diene [3] and laidFigure 3 Production of geraniol and geranic acid by P. putida
DSM 12264 expressing GES. Indicated are the concentrations of de
novo produced geraniol (blue) and geranic acid (red) over time
using P. putida DSM 12264 expressing GES. Cells were grown in
shake flasks in E2 medium (containing 10% LB and 30 mg/L
kanamycin, 4.6 g/L glycerol) at 30°C and GES expression was
induced 3 h after inoculation with 0.2% (w/v) L-rhamnose. Triangles
indicate P. putida DSM 12264 with empty plasmid, circles indicate P.
putida DSM 12264 pMiS1-ges. Geraniol and geranic acid concentrations
were determined via HPLC over time. Mean values of two independent
experiments, indicated by error bars, are given. For detailed statistical
analysis, please see Additional file 3.the foundation for a series of step-wise further strain
improvements.
Following this concept to increase carbon flux towards
terpenoid synthesis, 6 genes encoding the MVA pathway
of M. xanthus leading from acetyl-CoA to isopentenyl
pyrophosphate (IPP) and dimethylallyl pyrophosphate
(DMAPP) together with the geraniol synthase gene from
O. basilicum were introduced into P. putida DSM 12264
in the present work. In contrast to previously shown
experiments, twice the amount of glycercol (9.2 g/L
instead of 4.6 g/L) was used for the medium to prevent
growth-limiting effects. The geraniol production/depletion
and concurrent geranic acid production profiles obtained
(Figure 4) look similar to the profiles of the strain lacking
the MVA pathway (Figure 3) but with significantly higher
maximum terpenoid concentrations (p <0.01, Tukey’s
HSD, Additional file 4). About 3 μM of geraniol accumu-
lated in 5 h after induction of heterologous gene expres-
sion. Geraniol concentration decreased after 5 h and was
not detectable anymore after 2 days, whereas geranic acid
steadily accumulated concurrently. A maximum concen-
tration of 215 μM geranic acid was obtained after 2 days.
Geranic acid production in the fed-batch bioreactor
P. putida DSM 12264 coexpressing GES and the MVA
pathway was tested under controlled conditions in the
bioreactor. After cells were grown for 24 h, protein ex-
pression was induced (t = 0). Samples for OD600 measure-
ment and HPLC analysis were taken over time for threeFigure 4 Production of geraniol and geranic acid by P. putida
DSM 12264 expressing GES and MVA. Indicated are the
concentrations of de novo produced geraniol (blue) and geranic acid
(red) over time using P. putida DSM 12264 expressing GES and MVA.
Cells were grown in shake flasks in E2 medium (containing 10% LB,
30 mg/L kanamycin and 9.2 g/L glycerol) at 30°C and heterologous
gene expression was induced 3 h after inoculation with 0.2% (w/v)
L-rhamnose. Geraniol and geranic acid concentrations were
determined via HPLC over time. Mean values of two independent
experiments, indicated by error bars, are given. For detailed
statistical analysis, please see Additional file 4.
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ity of OD600 66 was obtained after 24 h and a total of
1.15 mM geranic acid was produced after 2 days.
Discussion
P. putida DSM 12264 is a suitable microbe for geraniol to
geranic acid conversion
Many P. putida strains are known, which are highly
tolerant towards organic solvents. Since bacterial mono-
terpenoid toxicity is an obstacle for E. coli and S. cerevisiae
as terpenoid production hosts [32,36], P. putida DSM
12264, known for its high monoterpenoid tolerance [24],
was tested as a host for de novo production of geranic
acid. This strain turned out to be significantly more toler-
ant to geranic acid than E. coli and S. cerevisiae (Figure 1).
Besides, the pseudomonad is able to completely and effi-
ciently oxidize up to 16 mM geraniol. As a consequence,
inhibition of cell growth by geraniol as an intermediate is
not expected to be a bottleneck during de novo production
of geranic acid.
Some pseudomonads, such as P. aeruginosa, P. citro-
nellolis and P. mendocina, are known to utilize geraniol
and geranic acid as sole carbon sources whereas P. putida
is usually not able to assimilate neither of the substances
[37,38]. Oxidation of geraniol to the corresponding acid
by the upper part of the acyclic terpene utilization (atu)
pathway is assumed to be the inital step in geraniol
degradation [39]. Furthermore, a pyrroloquinoline quin-
one dependent alcohol dehydrogenase (QEDH) encoded
by the exaA gene was found to participate in geraniolFigure 5 Production of geranic acid by P. putida DSM 12264
expressing GES and MVA in a fed-batch bioprocess. Indicated
are the OD600 value (blue) and the concentration of de novo
produced geranic acid (red) over time using P. putida DSM 12264
expressing GES and MVA in the bioreactor. Cells were grown in a
bioreactor in E2 medium (containing 10% LB and 30 mg/L
kanamycin, 4.6 g/L glycerol) for 24 h before induction of gene
expression with 0.2% (w/v) L-rhamnose (t = 0). Geranic acid
concentration was determined via HPLC over time. Mean values of
two independent experiments, indicated by error bars, are given.oxidation in P. aeruginosa as well [40]. Therefore, oxi-
doreductases homologous to AtuB and AtuG of the atu
pathway [39] or QEDH [40] are likely to be responsible
for geraniol oxidation in P. putida DSM 12264 as well,
although it cannot be excluded, whether nonspecific
oxidoreductases are involved as well. These oxidoreduc-
tases are promising candidates for further optimization of
the geraniol oxidation power of the strain.
The demonstration of high geranic acid tolerance
combined with an efficient geraniol oxidation pathway
and the inability to degrade geranic acid laid the founda-
tion to engineer P. putida DSM 12264 towards a micro-
bial cell factory for de novo production of geranic acid.
De novo production of geranic acid by recombinant P.
putida DSM 12264
Geraniol synthase (GES) from O. basilicum was shown
to be functionally expressed in E. coli and S. cerevisiae
and de novo geraniol production was already successfully
demonstrated in both microbes [31,41,42]. Karst and
co-workers obtained a de novo geraniol concentration of
about 10 mg/L in yeast after optimization of GPP synthase
activity to increase the GPP pool [43] and optimization of
GES activity [44]. More recently, a geraniol concentration
of 36 mg/L was reported for yeast after metabolic engin-
eering of the intrinsic MVA pathway [45]. In the present
work, naturally geraniol oxidizing P. putida DSM 12264
was chosen as host for functional expression of GES to
accomplish direct de novo production of the desired oxi-
dation product of geraniol, geranic acid. Glycerol was
chosen as the carbon source since this compound is cheap
and abundantly available as the main by-product of bio-
diesel production [46]. Transient accumulation of geraniol
indicated fast but delayed oxidation of the monoterpene
alcohol to geranic acid by endogenous enzymes. As the
product was found in the supernatant without significant
residual material left in the cells, product recovery in a
later bioprocess will be facilitated.
Metabolic engineering of pathways leading to elevated
terpenoid precursor levels is a common approach in
biotechnological terpenoid production [47]. In E. coli,
the recombinant MVA pathway from S. cerevisiae
proved to be efficient [3,48], even though expression of
some of the yeast enzymes revealed to be not balanced
in E. coli [8,49,50]. Approaches replacing yeast genes hmgr
and hmgs with their orthologues from Staphylococcus aur-
eus [51,52] led to significant increases in production rates.
An entirely prokaryotic MVA pathway was shown to en-
hance the coenzyme Q10 production in E. coli [53]. The
bacterium M. xanthus possesses a complete MVA path-
way where 5 of the 6 required genes are organized in an
operon that eases a straightforward cloning procedure.
We therefore tested the influence of the MVA pathway of
M. xanthus on geranic acid production in P. putida DSM
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215 μM (36.2 mg/L) of geranic acid was obtained after
2 days of cultivation, corresponding to a more than
10-fold increase compared to the strain without M.
xanthus MVA pathway (p <0.01, Tukey’s HSD, Additional
file 4), demonstrating the pronounced positive effect of
the MVA pathway on terpenoid production in P. putida
DSM 12264. Since the intrinsic GPP pool is assumed to
be limiting as well, additional GPP synthases such as
ERG20-2 from S. cerevisiae [54] or IDS from Picea abies
[55] may further increase product formation. Further-
more, ribosome binding sites (RBS) of the FPP biosyn-
thesis genes can be optimized, which led to a considerable
increase in amorphadiene yield with E. coli [56]. Besides,
homologous overexpression of the MEP pathway to en-
hance terpenoid precursors as an alternative route can be
considered as well, since overexpression of this pathway
was shown to benefit carotene production in P. putida
KT2440 [57]. These options will be content of further
work to enhance product formation.
De novo production of geranic acid with P. putida DSM
12264 in a fed-batch bioreactor
Since P. putida DSM 12264 was previously shown to be
an efficient whole cell biocatalyst for limonene biotrans-
formation under process conditions due to high monoter-
penoid tolerance and ease of cultivation [24], we tested
the performance of the recombinant P. putida bearing
GES and the MVA pathway in the bioreactor as well.
Geranic acid concentration increased rapidly and continu-
ously after induction. A maximum OD600 of 66 after 24 h
and a final concentration of 1.15 mM (193 mg/L) geranic
acid were obtained after 48 h, corresponding to a specific
product yield of 9.7 mg/g cdw, below but in the same
order of magnitude as compared with the value of
13.9 mg/g cdw obtained in the shake flask experiments.
Comparable product yields between 7 and 17.6 mg/g
cdw were recently obtained for limonene with different
E. coli strains harboring the MVA pathway [58]. Signifi-
cantly higher ratios of about 230 mg/g cdw of limonene
and about 65 mg/g cdw of perillyl alcohol were obtained
by Alonso-Gutierrez and co-workers [51] with an engi-
neered MVA containing E. coli strain, assuming an
average correlation of cdw [g/L] = OD600 [−] ∙0.46 [59].
In both experiments, a second organic phase was used
for in situ product removal of the produced monoter-
penoids. Since P. putida DSM 12264 is able to tolerate
distinctly higher concentrations of geranic acid (see
Figure 1) as those produced in the present work, inhi-
biting effects of the product on cell growth can be
excluded. In contrast, engineered S. cerevisiae would
have probably not been capable of producing a similar
amount of product, as the yeast growth was already
severely inhibited by 1 mM geranic acid (only 36% ofμmax0, see Figure 1). E. coli wildtype significantly lost
viability above 5 mM geranic acid, indicating that it
could still be a production host for geranic acid com-
petitive to our current data obtained with P. putida
DSM 12264, providing that an additional heterologous
expression of a geraniol-to-geranic acid pathway is
feasible in E. coli. On the contrary, if the target molecules
are not monoterpenoic acids but instead monoterpene
alcohols, such as perillyl alcohol or geraniol, the pro-
nounced oxidative capacity of P. putida DSM 12264
will be a disadvantage due to unwanted overoxidation
as shown in a recent comparison of recombinant E. coli
and P. putida for whole cell bioconversion of limonene
to perillyl alcohol [60]. Identifying endogenous genes
responsible for overoxidation, e.g. those for the geraniol-
to-geranic acid conversion, followed by a targeted knock-
out could be a solution if specific monoterpene alcohols
(or ketones/aldehydes) are sought. The identification of
oxidizing enzymes may also lead to a modular pathway
design for P. putida to de novo synthesize monoterpe-
noids of a desired oxyfunctionalization degree. Here, we
intentionally coupled an MVA pathway enhanced terpen-
oid biosynthesis with a plant monoterpene synthase and a
so far unknown endogenous oxyfunctionalization pathway
in P. putida. In pre-investigations (Becher et al., unpub-
lished), P. putida DSM 12264 heterologously expressing
Mentha spicata limonene synthase instead of O. basilicum
geraniol synthase produced small amounts of perillic acid,
as expected. However, since limonene, in contrast to gera-
niol, is a very cheap natural precursor abundantly available
from renewable resources (by-product of the citrus
processing industry) and perillic acid can be efficiently
obtained in concentrations of up to 30 g/L through
bioconversion of limonene as shown in our previous
work [24], we focused on geranic acid in the present
work. Nevertheless, this underpins the feasibility of
turning P. putida DSM 12264 into a cell factory for de
novo production of different monoterpenoids, especially
different monoterpenoic acids. So far, the potential of P.
putida DSM 12264 for geranic acid production has not
yet been fully harnessed, as the strain is not significantly
growth-inhibited at product concentrations of up to
15 mM. Therefore, there is still room for a 10-fold in-
crease in final product concentration by metabolic en-
gineering means without expecting a negative impact
on the growth performance of the host. The maximum
cell density of OD600 66 corresponding to 19.8 g cdw/L
obtained with P. putida DSM 12264 in the fed-batch
process is still moderate. Thus, optimization of the
bioprocess based on published protocols for high-cell
density fermentations of P. putida [61-64] should be
feasible and may lead to significant higher biomass and
product concentrations. Finally, solvent tolerant bac-
teria such as P. putida are ideal microbes to be used in
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presence of adsorbers [24] for in situ product removal,
which facilitates the development of high-perfomance in-
tegrated bioprocesses.
Conclusion
Engineering P. putida for de novo production of a
monoterpenoid was shown for the first time. The solvent
tolerant strain P. putida DSM 12264, originally used as a
robust wildtype whole cell biocatalyst for production of
perillic acid from limonene [24], was shown to possess a
strong oxidative capacity and efficiently converted geraniol
to geranic acid. Introducing MVA pathway and geraniol
synthase turned P. putida DSM 12264 into a microbial
cell factory for de novo production of geranic acid from
the renewable carbon source glycerol. P. putida DSM
12264 was shown to be of superior geranic acid tolerance
compared to the conventional microbial hosts E. coli and
S. cerevisiae. Being tolerant against different monoter-
penoids, viable even in the presence of a separate
monoterpenoid phase under process conditions [24],
and genetically well accessible make this strain a highly
promising platform for monoterpenoid production in
the future.
Materials and methods
Chemicals, wildtype strains and media
Geranic acid (85%), geraniol (98%) and thymol (99%) were
purchased from Sigma-Aldrich (Taufkirchen, Germany).
(L)-(+)-Rhamnose monohydrate, glycerol and hexane
(≥99%) were purchased from Carl Roth (Karlsruhe,
Germany).
For growth assays, P. putida strain DSM 12264, S.
cerevisiae strain CEN.PK2-1C [65] and E. coli strain
DH5α [66] were used. Each organism was grown in
complex medium: terrific broth (TB) for P. putida,
yeast medium (YM) for S. cerevisiae and lysogeny
broth (LB) for E. coli. Additionally, LB was used as pre-
culture medium for geranic acid production experi-
ments with P. putida. For whole cell de novo syntheses,
E2 medium [25] containing 10% LB was used. For PCR
amplification of the MVA pathway genes, DNA of M.
xanthus DSM 16526 was used.
Plasmid construction and transformation
The gene encoding a GES lacking the signal peptide
encoding region from O. basilicum was amplified from
plasmid pMO5 [41]. The 6 genes of the MVA pathway,
namely HMG-CoA synthase (hmgs), HMG-CoA reduc-
tase (hmgr), mevalonate kinase (mvk), phosphomevalo-
nate kinase (pmvk), diphosphomevalonate decarboxylase
(mvd) and isopentenyldiphosphateisomerase (idi), were
amplified from genomic DNA of M. xanthus. Primers
used in this study are summarized in Table 1.For gene expression in P. putida DSM 12264, plasmid
pMiS1 was used which was derived from pJeM1 [67] by
exchange of the eGFP gene with a synthetically con-
structed multiple cloning site sequence. Single stranded
sense primer pJeM1-MCS-f and antisense strand primer
pJeM1-MCS-r comprising the rhamnose-inducible pro-
moter rhaPBAD, a ribosome binding site, a multiple clon-
ing site (MCS) and 5′-phosphorylations were ordered
from Sigma Aldrich. The promoter and the ribosome
binding site were re-inserted with the new MCS since
the original parts were cut out with egfp due to restric-
tion sites limitations. After hybridization, the DNA frag-
ment was ligated into EcoRI and HindIII precut pJeM1
backbone.
The ges gene was amplified from pMO5 [41] using
primers GES-fwd and GES-rev and cloned via KpnI and
SacI into pMiS1 to give pMiS1-ges. The MVA pathway
genes of M. xanthus are genomically organized as a single
gene (hmgs) and an operon containing the rest of the
genes (idi, hmgr, mvd, mvk, pmvk). For cloning of these
MVA pathway genes into pMiS1, hmgs was first amplified
from genomic M. xanthus DNA using the primers
pMiS1-hmgs-f (containing an upstream Shine-Dalgarno
sequence) and pMiS1-hmgs-r and cloned via BamHI
and HindIII into pMiS1 yielding pMiS1-hmgs. Then, the
operon (containing all other genes) was cloned sequen-
tially into pUC18. Three amplifications were performed
using primers pMiS1-MVA-f1, pMiS1-MVA-r1 (part1,
containing an upstream Shine-Dalgarno-sequence), pMiS1-
MVA-f2, pMiS1-MVA-r2 (part 2) and pMiS1-MVA-f3,
pMiS1-MVA-r3 (part 3). Parts were ligated using BamHI,
SacI and EcoRI as restriction sites. The new operon
comprising all 5 genes was then cut from resulting
pUC18-mva-op via AvrII and HindIII and ligated into
pMiS1-hmgs to give pMiS1-mva. The ges gene was then
cut from pMiS1-ges and ligated into pMiS1-mva using
PmeI and BamHI to give pMiS1-ges-mva. For a schematic
of the cloning strategy, please see Additional file 2.
P. putida DSM 12264 was transformed by electropor-
ation [68]. Recombinant cells were selected on LB agar
containing 30 mg/L kanamycin.
Growth, metabolization and bioconversion assays
The inhibitory effect of geranic acid on the growth of E.
coli, S. cerevisiae or P. putida was investigated. To avoid
terpenoid evaporation, 100 mL baffled flasks with screw
caps were used for growth assays. For all microbes,
20 mL complex medium were inoculated with an optical
density (OD600) of 0.2 from an overnight preculture and
cultivated at 180 rpm shaking (2.5 cm displacement). S.
cerevisiae and P. putida were cultivated at 30°C; E. coli
was cultivated at 37°C. For each organism, a specific
range of geranic acid concentrations was chosen, in
which inhibiting effects occur. Geranic acid was added
Table 1 Primers used in this study








GES-fwd GATCGGTACCATGCCTCTAAGTTCAACTC This work
GES-rev GATCGAGCTCTTATTGAGTGAAGAAGAGG This work
pMiS1-hmgs-f GATCGGATCCAGGAGGAATAATATGAAGAAGCGCGTGGGAATC This work
pMiS1-hmgs-r GATCAAGCTTCCTAGGTCAGTTCCCTTCGGCGTAC This work
pMiS1-MVA-f1 ATCTGGATCCTAGGAGGAATAATATGGGCGACGACATCACTG This work
pMiS1-MVA-r1 AACACCATGGCGAGCTCTC This work
pMiS1-MVA-f2 GAGAGCTCGCCATGGTGTT This work
pMiS1-MVA-r2 GTGCCCGTTGAGCTCCACCT This work
pMiS1-MVA-f3 AGGTGGAGCTCAACGGGCAC This work
pMiS1-MVA-r3 ATCGAATTCAAGCTTTCAGCTCAGCGCGCGCACC This work
Italics and bold parts represent first and second (if available) restriction site used for cloning, respectively. pJeM1-MCS-f and pJeM1-MCS-r were 5’-phosphorylated
([phos]) and used as sense and antisense DNA strands to exchange egfp of pJeM1 with an insert comprising the rhamnose-inducible promoter rhaPBAD, a ribosome
binding site and an MCS. For more details of the cloning strategy, see Additional file 2.
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of the exponential growth phase (after 1 h of cultivation
for E. coli and P. putida and after 3 h for S. cerevisiae).
Controls with the highest applied ethanol concentrations
were tested simultaneously and no inhibiting effects of
ethanol on microbial growth could be observed. Samples
were taken during exponential growth phase every 30 min
for E. coli and P. putida and every hour for S. cerevisiae
and OD600 was determined. All experiments were per-
formed in duplicates. For each growth curve, μmax was de-
termined at the exponential growth phase immediately
after geranic acid addition and divided by μmax0 of the cul-
ture without geranic acid.
For metabolization tests with geraniol as sole carbon
source, P. putida cells were grown in complex medium
overnight and plated on E2 minimal medium lacking
glycerol. Geraniol was applied as vapor phase. Water was
used as negative control and p-cymene as positive control,
since P. putida DSM 12264 is known to grow on this aro-
matic compound [25]. Cell growth was monitored for
94 h at 30°C. For metabolization tests with geranic acid as
the sole carbon source, 20 mL E2 medium lacking glycerol
with 20 mM geranic acid was inoculated using 1 mL of a
P. putida overnight culture. No carbon source was applied
for the negative control and 20 mM p-cymene was applied
as positive control. Cell growth was monitored via OD600
determination for 144 h at 30°C.
Stability tests with geranic acid and whole cell biotrans-
formation with geraniol were performed with P. putida
cells in 50 mL and 20 mL E2 medium, respectively, con-
taining corresponding terpenoid concentrations. Medium
was inoculated with TB preculture of P. putida at an initialOD600 of 0.2. Geranic acid concentrations at different time
points were determined by HPLC analysis.
De novo geranic acid synthesis
All cultures of recombinant P. putida strains contained
30 mg/L kanamycin for plasmid selection. Precultures
were inoculated from cryo cultures using 5 mL LB with
antibiotic and incubated overnight at 30°C and 180 rpm
shaking (2.5 cm displacement). Main cultures of 50 mL
E2 medium (containing 10% LB) in 300 mL Erlenmeyer
flasks were then inoculated using 0.5 mL of precultures.
Main cultures were incubated at 30°C and 180 rpm
shaking frequency (2.5 cm displacement). Gene expres-
sion was induced after 3 h with 0.2% (w/v) L-rhamnose.
Samples were taken and stored at −20°C until sample
preparation.
HPLC analysis
To P. putida culture samples of 500 μL or 1 mL, 50 μL
or 100 μL 1 M HCl were added, respectively, and ana-
lytes were extracted using 500 μL hexane containing
200 μM thymol as an internal standard. For bioconver-
sion assays, 1 mM thymol was used. Samples were cen-
trifuged (5 min, 18,000 g) and the organic phase was
analyzed by HPLC, consisting of a diode array detector
and a C-18 column (Alltech Alltima, C18, 5 μm, 250 ×
4,6 mm; C18 Precolumn, Grace GmbH and Co. KG,
Worms). Substances were separated isocratically using
acetonitrile/acidified water (containing 0.5% (v/v) 3 M
phosphoric acid) in a ratio of 55:45 (v/v) as mobile
phase. Geraniol and thymol were monitored at 202 nm,
geranic acid at 217 nm.
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De novo geranic acid production in the bioreactor was
performed using a DASGIP SR0700ODLS system
(DASGIP, Jülich, Germany). 5 mL of LB precultures
with 30 mg/L kanamycin were used to inoculate
500 mL E2 medium (containing 10% LB and 30 mg/L
kanamycin). Main cultures were incubated for 24 h at
30°C with 50 mL/h aeration and 30% saturation of
dissolved oxygen (DO). Glycerol (612 g/L) and MgSO4
(10 g/L) feed was triggered by DO (50 mL/h feed rate).
The pH was maintained at 6.9 by automatic addition of
ammonia. GES expression was induced by addition of
L-rhamnose after 24 h of incubation (t = 0) to a con-
centration of 0.2% (w/v) and aeration rate was lowered
to 10 mL/h, DO limited to a saturation of 10% and a
feed rates of 10 mL/h (glycerol and MgSO4) for the
production phase. Samples were taken over time and
prepared for HPLC analysis as described above.
Additional files
Additional file 1: Statistical analysis of the dataset of
biotransformation of geraniol to geranic acid by wildtype
P. putida DSM 12264 (Figure 2).
Additional file 2: Schematic of the cloning procedure leading to
the plasmids pMiS1, pMiS1-ges, pUC18-mva-op, pMiS1-hmgs,
pMiS1-mva and pMiS1-ges-mva, respectively.
Additional file 3: Statistical analysis of the dataset of de novo
production of geranic acid by P. putida DSM 12264 harboring ges
(Figure 3).
Additional file 4: Statistical analysis of the maximum concentration
of geranic acid produced by P. putida DSM 12264 harboring ges and
by P. putida DSM 12264 harboring ges and mva (Figures 3 and 4).
Abbreviations
GES: Geraniol synthase; MVA: Mevalonate; OD600: Optical density at 600 nm;
GPP: Geranyl pyrophosphate; FPP: Farnesyl pyrophosphate; IPP: Isopentenyl
pyrophosphate; DMAPP: Dimethylallyl pyrophosphate; HPLC: High pressure
liquid chromatography; DO: Dissolved oxygen.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DB and JM performed the growth experiments and together with MB
drafted the manuscript. DB, JM and PL carried out the plasmid construction.
JM was responsible for editorial handling and statistical analysis. PL
performed the shake flask experiments with production strains. SD
performed the fermentation experiments. JM, KT and HS performed the
terpenoid bioconversion and metabolization experiments. JS conceived the
work and together with MB designed and supervised the experiments and
they wrote the final manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The authors thank Prof. Josef Altenbuchner (University of Stuttgart) for kindly
providing plasmid pJeM1. The authors thank Prof. Francis Karst (University of
Strasbourg) for kindly providing plasmid pMO5. This work was supported by
FNR, Fachagentur für nachwachsende Rohstoffe e.V., (No. 22040011).
Received: 25 July 2014 Accepted: 19 November 2014References
1. Bution ML, Molina G, Abrahao MR, Pastore GM: Genetic and metabolic
engineering of microorganisms for the development of new flavor
compounds from terpenic substrates. Crit Rev Biotechnol 2014:1–13.
doi:10.3109/07388551.2013.855161
2. Breitmaier E: Terpene: Aromen, Düfte, Pharmaka, Pheromone. Weinheim:
Wiley-VCH; 2005.
3. Martin VJ, Pitera DJ, Withers ST, Newman JD, Keasling JD: Engineering a
mevalonate pathway in Escherichia coli for production of terpenoids. Nat
Biotechnol 2003, 21:796–802.
4. Shiba Y, Paradise EM, Kirby J, Ro DK, Keasling JD: Engineering of the
pyruvate dehydrogenase bypass in Saccharomyces cerevisiae for
high-level production of isoprenoids. Metab Eng 2007, 9:160–168.
5. Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, Ho KA,
Eachus RA, Ham TS, Kirby J, Chang MC, Withers ST, Shiba Y, Sarpong R,
Keasling JD: Production of the antimalarial drug precursor artemisinic
acid in engineered yeast. Nature 2006, 440:940–943.
6. Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, Leavell
MD, Tai A, Main A, Eng D, Polichuk DR, Teoh KH, Reed DW, Treynor T,
Lenihan J, Fleck M, Bajad S, Dang G, Dengrove D, Diola D, Dorin G, Ellens
KW, Fickes S, Galazzo J, Gaucher SP, Geistlinger T, Henry R, Hepp M, Horning
T, Iqbal T, et al: High-level semi-synthetic production of the potent
antimalarial artemisinin. Nature 2013, 496:528–532.
7. Scalcinati G, Knuf C, Partow S, Chen Y, Maury J, Schalk M, Daviet L, Nielsen J,
Siewers V: Dynamic control of gene expression in Saccharomyces
cerevisiae engineered for the production of plant sesquitepene α-
santalene in a fed-batch mode. Metab Eng 2012, 14:91–103.
8. Anthony JR, Anthony LC, Nowroozi F, Kwon G, Newman JD, Keasling JD:
Optimization of the mevalonate-based isoprenoid biosynthetic pathway
in Escherichia coli for production of the anti-malarial drug precursor
amorpha-4, 11-diene. Metab Eng 2009, 11:13–19.
9. Peralta-Yahya PP, Ouellet M, Chan R, Mukhopadhyay A, Keasling JD, Lee TS:
Identification and microbial production of a terpene-based advanced
biofuel. Nat Commun 2011, 2:483.
10. Sarria S, Wong B, Martin HG, Keasling JD, Peralta-Yahya P: Microbial synthesis
of pinene. ACS Synth Biol 2014 in press (DOI:10.1021/sb4001382).
11. Yang J, Nie Q, Ren M, Feng H, Jiang X, Zheng Y, Liu M, Zhang H, Xian M:
Metabolic engineering of Escherichia coli for the biosynthesis of
alpha-pinene. Biotechnol Biofuels 2013, 6:60.
12. van der Werf MJ, De Bont JAM, Leak DJ: Opportunities in microbial
biotransformation of monoterpenes. In Biotechnology of Aroma
Compounds, Volume 55. Edited by Scheper T. Berlin: Springer; 1997:283.
13. Tippmann S, Chen Y, Siewers V, Nielsen J: From flavors and
pharmaceuticals to advanced biofuels: production of isoprenoids in
Saccharomyces cerevisiae. Biotechnol J 2013, 8:1435–1444.
14. Trombetta D, Castelli F, Sarpietro MG, Venuti V, Cristani M, Daniele C, Saija A,
Mazzanti G, Bisignano G: Mechanisms of antibacterial action of three
monoterpenes. Antimicrob Agents Chemother 2005, 49:2474–2478.
15. Uribe S, Ramirez J, Peña A: Effects of beta-pinene on yeast membrane
functions. J Bacteriol 1985, 161:1195–1200.
16. Andrews RE, Parks LW, Spence KD: Some effects of Douglas fir terpenes
on certain microorganisms. Appl Environ Microbiol 1980, 40:301–304.
17. Brennan TC, Kromer JO, Nielsen LK: Physiological and transcriptional responses
of Saccharomyces cerevisiae to d-limonene show changes to the cell wall but
not to the plasma membrane. Appl Environ Microbiol 2013, 79:3590–3600.
18. Ramos JL, Duque E, Gallegos M-T, Godoy P, Ramos-González MI, Rojas A,
Terán W, Segura A: Mechanisms of solvent tolerance in gram-negative
bacteria. Annu Rev Microbiol 2002, 56:743–768.
19. Heipieper HJ, Neumann G, Cornelissen S, Meinhardt F: Solvent-tolerant
bacteria for biotransformations in two-phase fermentation systems. Appl
Microbiol Biotechnol 2007, 74:961–973.
20. Poblete-Castro I, Becker J, Dohnt K, Dos Santos VM, Wittmann C: Industrial
biotechnology of Pseudomonas putida and related species. Appl Microbiol
Biotechnol 2012, 93:2279–2290.
21. Wierckx NJ, Ballerstedt H, de Bont JA, Wery J: Engineering of solvent-tolerant
Pseudomonas putida S12 for bioproduction of phenol from glucose. Appl
Environ Microbiol 2005, 71:8221–8227.
22. Meijnen JP, Verhoef S, Briedjlal AA, de Winde JH, Ruijssenaars HJ: Improved
p-hydroxybenzoate production by engineered Pseudomonas putida S12
by using a mixed-substrate feeding strategy. Appl Microbiol Biotechnol
2011, 90:885–893.
Mi et al. Microbial Cell Factories 2014, 13:170 Page 10 of 11
http://www.microbialcellfactories.com/content/13/1/17023. Faizal I, Dozen K, Hong CS, Kuroda A, Takiguchi N, Ohtake H, Takeda K,
Tsunekawa H, Kato J: Isolation and characterization of solvent-tolerant
Pseudomonas putida strain T-57, and its application to biotransformation
of toluene to cresol in a two-phase (organic-aqueous) system. J Ind
Microbiol Biotechnol 2005, 32:542–547.
24. Mirata MA, Heerd D, Schrader J: Integrated bioprocess for the oxidation of
limonene to perillic acid with Pseudomonas putida DSM 12264. Process
Biochem 2009, 44:764–771.
25. Speelmans G, Bijlsma A, Eggink G: Limonene bioconversion to high
concentrations of a single and stable product, perillic acid, by a
solvent-resistant Pseudomonas putida strain. Appl Microbiol Biotechnol
1998, 50:538–544.
26. Bedoukian PZ: Perfumery and Flavoring Synthetics. Wheaton: Allured
Publishing Corporation; 1986.
27. Schrader J: Microbial Flavour Production. In Flavours and Fragrances. Edited
by Berger RG. Berlin: Springer; 2007:507–574.
28. Yang T, Stoopen G, Yalpani N, Vervoort J, de Vos R, Voster A, Verstappen
FW, Bouwmeester HJ, Jongsma MA: Metabolic engineering of geranic acid
in maize to achieve fungal resistance is compromised by novel
glycosylation patterns. Metab Eng 2011, 13:414–425.
29. Wang N, Hebert DN: Tyrosinase maturation through the mammalian
secretory pathway: bringing color to life. Pigment Cell Res 2006, 19:3–18.
30. Choi SY: Inhibitory effects of geranic acid derivatives on melanin
biosynthesis. J Cosmet Sci 2012, 63:351–358.
31. Iijima Y, Gang DR, Fridman E, Lewinsohn E, Pichersky E: Characterization of
geraniol synthase from the peltate glands of sweet basil. Plant Physiol
2004, 134:370–379.
32. Brennan TCR, Turner CD, Krömer JO, Nielsen LK: Alleviating monoterpene
toxicity using a two-phase extractive fermentation for the bioproduction
of jet fuel mixtures in Saccharomyces cerevisiae. Biotechnol Bioeng 2012,
109:2513–2522.
33. Nelson KE, Weinel C, Paulsen IT, Dodson RJ, Hilbert H, Santos VAP M d,
Fouts DE, Gill SR, Pop M, Holmes M, Brinkac L, Beanan M, DeBoy RT,
Daugherty S, Kolonay J, Madupu R, Nelson W, White O, Peterson J, Khouri H,
Hance I, Lee PC, Holtzapple E, Scanlan D, Tran K, Moazzez A, Utterback T,
Rizzo M, Lee K, Kosack D, et al: Complete genome sequence and
comparative analysis of the metabolically versatile Pseudomonas putida
KT2440. Environ Microbiol 2002, 4:799–808.
34. Schrader J, Berger RG: Biotechnological production of terpenoid flavor
and fragrance compounds. In Biotechnology: Special Processes, Volume 10.
Edited by Rehm HJ, Reed G. Weinheim: Wiley-VCH; 2001:373–422.
35. Chandran SS, Kealey JT, Reeves CD: Microbial production of isoprenoids.
Process Biochem 2011, 46:1703–1710.
36. Dunlop MJ, Dossani ZY, Szmidt HL, Chu HC, Lee TS, Keasling JD, Hadi MZ,
Mukhopadhyay A: Engineering microbial biofuel tolerance and export
using efflux pumps. Mol Sys Biol 2011, 7:487.
37. Cantwell SG, Lau EP, Watt DS, Fall RR: Biodegradation of acyclic
isoprenoids by Pseudomonas species. J Bacteriol 1978, 135:324–333.
38. Vandenbergh PA, Wright AM: Plasmid involvement in acyclic isoprenoid
metabolism by Pseudomonas putida. Appl Environ Microbiol 1983,
45:1953–1955.
39. Forster-Fromme K, Jendrossek D: Identification and characterization of the
acyclic terpene utilization gene cluster of Pseudomonas citronellolis. FEMS
Microbiol Lett 2006, 264:220–225.
40. Chattopadhyay A, Förster-Fromme K, Jendrossek D: PQQ-Dependent
Alcohol Dehydrogenase (QEDH) of Pseudomonas aeruginosa is involved
in catabolism of acyclic terpenes. J Basic Microbiol 2010, 50:119–124.
41. Oswald M, Fischer M, Dirninger N, Karst F: Monoterpenoid biosynthesis in
Saccharomyces cerevisiae. FEMS Yeast Res 2007, 7:413–421.
42. Fischer MJ, Meyer S, Claudel P, Perrin M, Ginglinger JF, Gertz C, Masson JE,
Werck-Reinhardt D, Hugueney P, Karst F: Specificity of Ocimum basilicum
geraniol synthase modified by its expression in different heterologous
systems. J Biotech 2013, 163:24–29.
43. Fischer MJ, Meyer S, Claudel P, Bergdoll M, Karst F: Metabolic engineering of
monoterpene synthesis in yeast. Biotechnol Bioeng 2011, 108:1883–1892.
44. Fischer MJ, Meyer S, Claudel P, Steyer D, Bergdoll M, Hugueney P:
Determination of amino-acidic positions important for Ocimum basilicum
geraniol synthase activity. Adv Biosci Biotechnol 2013, 4:242–249.
45. Liu J, Zhang W, Du G, Chen J, Zhou J: Overproduction of geraniol by
enhanced precursor supply in Saccharomyces cerevisiae. J Biotech 2013,
168:446–451.46. da Silva GP, Mack M, Contiero J: Glycerol: a promising and abundant
carbon source for industrial microbiology. Biotechnol Adv 2009, 27:30–39.
47. Peralta-Yahya PP, Zhang F, Del Cardayre SB, Keasling JD: Microbial
engineering for the production of advanced biofuels. Nature 2012,
488:320–328.
48. Morrone D, Lowry L, Determan MK, Hershey DM, Xu M, Peters RJ:
Increasing diterpene yield with a modular metabolic engineering
system in E. coli: comparison of MEV and MEP isoprenoid
precursor pathway engineering. Appl Microbiol Biotechnol 2010,
85:1893–1906.
49. Pitera DJ, Paddon CJ, Newman JD, Keasling JD: Balancing a heterologous
mevalonate pathway for improved isoprenoid production in Escherichia
coli. Metab Eng 2007, 9:193–207.
50. Redding-Johanson AM, Batth TS, Chan R, Krupa R, Szmidt HL, Adams PD,
Keasling JD, Soon Lee T, Mukhopadhyay A, Petzold CJ: Targeted
proteomics for metabolic pathway optimization: application to terpene
production. Metab Eng 2011, 13:194–203.
51. Alonso-Gutierrez J, Chan R, Batth TS, Adams PD, Keasling JD, Petzold CJ, Lee
TS: Metabolic engineering of Escherichia coli for limonene and perillyl
alcohol production. Metab Eng 2013, 19:33–41.
52. Tsuruta H, Paddon CJ, Eng D, Lenihan JR, Horning T, Anthony LC, Regentin
R, Keasling JD, Renninger NS, Newman JD: High-level production of
amorpha-4, 11-diene, a precursor of the antimalarial agent artemisinin,
in Escherichia coli. PLoS One 2009, 4:e4489.
53. Zahiri HS, Yoon SH, Keasling JD, Lee SH, Won Kim S, Yoon SC, Shin
YC: Coenzyme Q10 production in recombinant Escherichia coli
strains engineered with a heterologous decaprenyl diphosphate
synthase gene and foreign mevalonate pathway. Metab Eng 2006,
8:406–416.
54. Blanchard L, Karst F: Characterization of a lysine-to-glutamic acid
mutation in a conservative sequence of farnesyl diphosphate synthase
from Saccharomyces cerevisiae. Gene 1993, 125:185–189.
55. Schmidt A, Gershenzon J: Cloning and characterization of two different
types of geranyl diphosphate synthases from Norway spruce
(Picea abies). Phytochemistry 2008, 69:49–57.
56. Nowroozi F, Baidoo EK, Ermakov S, Redding-Johanson A, Batth T, Petzold C,
Keasling J: Metabolic pathway optimization using ribosome binding site
variants and combinatorial gene assembly. Appl Microbiol Biotechnol 2013,
98:1567–1581.
57. Beuttler H, Hoffmann J, Jeske M, Hauer B, Schmid RD, Altenbuchner J,
Urlacher VB: Biosynthesis of zeaxanthin in recombinant Pseudomonas
putida. Appl Microbiol Biotechnol 2011, 89:1137–1147.
58. Willrodt C, David C, Cornelissen S, Buhler B, Julsing MK, Schmid A:
Engineering the productivity of recombinant Escherichia coli for
limonene formation from glycerol in minimal media. Biotechnol J 2014 in
press (doi:10.1002/biot.201400023).
59. Myers JA, Curtis BS, Curtis WR: Improving accuracy of cell and
chromophore concentration measurements using optical density. BMC
Biophys 2013, 6:4.
60. Cornelissen S, Julsing MK, Volmer J, Riechert O, Schmid A, Bühler B:
Whole-cell-based CYP153A6-catalyzed (S)-limonene hydroxylation
efficiency depends on host background and profits from monoterpene
uptake via AlkL. Biotechnol Bioeng 2013, 110:1282–1292.
61. Kim GJ, Lee IY, Choi DK, Yoon SC, Park YH: High cell density cultivation of
Pseudomonas putida MB01 using glucose. J Microbiol Biotechnol 1996,
6:221–224.
62. Thuesen MH, Norgaard A, Hansen AM, Caspersen MB, Christensen HE:
Expression of recombinant Pseudomonas stutzeri di-heme cytochrome c4
by high-cell-density fed-batch cultivation of Pseudomonas putida. Protein
Expr Purif 2003, 27:175–181.
63. Sun Z, Ramsay J, Guay M, Ramsay B: Automated feeding strategies for
high-cell-density fed-batch cultivation of Pseudomonas putida KT2440.
Appl Microbiol Biotechnol 2006, 71:423–431.
64. Ramadhan S, Matsui T, Nakano K, Minami H: High cell density
cultivation of Pseudomonas putida strain HKT554 and its application
for optically active sulfoxide production. Appl Microbiol Biotechnol
2013, 97:1903–1907.
65. Entian K-D, Kötter P: 23 yeast mutant and plasmid collections. Methods
Microbiol 1998, 26:431–449.
66. Bethesda_Research_Laboratories: BRL pUC host: E. coli DH5α™ competent
cells. Bethesda Res Lab Focus 1986, 8:9–12.
Mi et al. Microbial Cell Factories 2014, 13:170 Page 11 of 11
http://www.microbialcellfactories.com/content/13/1/17067. Jeske M, Altenbuchner J: The Escherichia coli rhamnose promoter rhaP
(BAD) is in Pseudomonas putida KT2440 independent of Crp-cAMP
activation. Appl Microbiol Biotechnol 2010, 85:1923–1933.
68. Choi KH, Kumar A, Schweizer HP: A 10-min method for preparation of
highly electrocompetent Pseudomonas aeruginosa cells: application for
DNA fragment transfer between chromosomes and plasmid
transformation. J Microbiol Methods 2006, 64:391–397.
doi:10.1186/s12934-014-0170-8
Cite this article as: Mi et al.: De novo production of the monoterpenoid
geranic acid by metabolically engineered Pseudomonas putida. Microbial
Cell Factories 2014 13:170.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
